Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc Analyst and Investor Day Transcript

Apr 17, 2019 / 12:00PM GMT
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Good morning, everyone. I am Emil Kakkis, in case you don't know, I'm sure most of you do know. I'm the CEO of Ultragenyx, and we're here to talk today about the progress we've been making as a company, both in the commercial products, in our gene therapy and in our early-stage program, to give you a deeper dive into what we're doing to change the lives of rare disease patients.

This is our legal warning and if you look at our SEC filings for the risks of investing in Ultragenyx.

The agenda today is really divided into 3 main sections. I'll do a brief overview right now, but there will be a commercial and late-stage pipeline to talk about Crysvita primarily, but also a little bit about the FAOD program.

We'll talk then in the gene therapy section, we'll hear about the current gene therapy programs. And we have some experts with us today to talk as well about those diseases, which will include a little bit of a discussion of Wilson, which is our next clinical gene therapy program.

In the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot